Use of combined treatment of PD-1 antibody and apatinib for treating triple negative breast cancer

摘要

The present invention relates to a use of a combined treatment of a PD-1 antibody and apatinib for treating triple negative breast cancer. In particular, the present invention relates to a use of an anti-PD-1 antibody in combination with apatinib in the preparation of a drug for triple negative breast cancer.